The Gap Junction Alpha 1 Protein pipeline drugs market research report outlays comprehensive information on the Gap Junction Alpha 1 Protein targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Gap Junction Alpha 1 Protein pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Ophthalmology, Cardiovascular, Oncology, and Dermatology which include the indications Diabetic Macular Edema, Dry (Atrophic) Macular Degeneration, Myocardial Ischemia, Stroke, Solid Tumor, Bone Cancer, Pressure Ulcers, and Scar. It also reviews key players involved in Gap Junction Alpha 1 Protein targeted therapeutics development with respective active and dormant or discontinued products.
The Gap Junction Alpha 1 Protein pipeline targets constitutes close to 13 molecules. Out of which, approximately 11 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 2, 2, 1, 4, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 2 molecule.
Gap Junction Alpha 1 Protein overview
Gap junction alpha-1 protein (GJA1), also known as connexin 43 (Cx43), is a protein that plays a role in cell-to-cell communication. It is one of 21 connexin proteins that form channels, or gap junctions, between cells. GJA1 is encoded by the GJA1 gene on chromosome 6 in humans.
For a complete picture of Gap Junction Alpha 1 Protein’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
